Month: January 2024

OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape

Written by Customer Service on January 25, 2024. Posted in Public Companies.

WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company’s growth plans. After nearly a decade of service, Gus Halas is retiring from his position as Chairperson of the Board. During his tenure, he played a pivotal role in shaping OptimizeRx’s success, and we extend our deepest gratitude for his commitment and leadership. Effective immediately, Lynn O’Connor Vos will assume the role of Chairperson of the Board, succeeding Mr. Halas. Ms. Vos has been a seasoned and respected member of the OptimizeRx Board since 2015. She brings...

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

Written by Customer Service on January 25, 2024. Posted in Public Companies.

InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for eligible patients.ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) — InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has launched The InflaRx Commitment Program (Commitment Program). Pursuant to the Commitment Program, the cost of GOHIBIC (vilobelimab) will be refunded for up to six (6) administered inpatient doses (the full treatment course) to institutions that meet the eligibility requirements*, for patients who were administered GOHIBIC in line with its EUA and who...

Global Air fryer Market to Surpass 1152.71 Billion by 2030 Driven by Increasing Emphasis on Health Consciousness

Written by Customer Service on January 25, 2024. Posted in Mergers And Acquisitions.

SkyQuest projects that the global air fryer market will attain a value of USD 1152.71 billion by 2030, with a CAGR of 7.2% during the forecast period (2023-2030). The rapid expansion of the global air fryer market can be primarily attributed to the continual introduction of new products featuring enhanced and innovative designs. Furthermore, the rise in consumer interest is expected to be fueled by the increasing emphasis on health consciousness and a heightened awareness of the numerous benefits of maintaining a balanced diet. Westford,USA, Jan. 25, 2024 (GLOBE NEWSWIRE) — According to SkyQuest, the growth of the global air fryer market can be primarily attributed to the introduction new products featuring enhanced designs. Furthermore, the rise in consumer interest is expected to be fueled by the increasing awareness of the importance...

Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy

Written by Customer Service on January 25, 2024. Posted in Public Companies.

BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) — Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD). The agreement covers several member countries, including Belgium, The Netherlands, and Ireland. It follows similar arrangements made with reimbursement authorities in the United Kingdom (UK), Italy, Germany, Sweden, Iceland, Finland and Norway, and is a key component of the company’s geographic expansion plans. MLD is a rare, fatal genetic disorder caused by a mutation in the gene responsible for encoding the enzyme arylsulfatase...

Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P.

Written by Customer Service on January 25, 2024. Posted in Public Companies.

Webinar to be hosted on January 31, 2024 at 1:00 pm. ET CHATHAM, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of TNX-102 SL for the management of fibromyalgia. The webinar will feature two esteemed thought leaders in the field of fibromyalgia and will be hosted by Alliance Global Partners.KOL Webinar DetailsTitle: KOL Discussion on Positive Phase 3 Data and Advantages Over Current TherapiesDate: Wednesday, January 31, 2024, at 1:00 p.m. ET.Participants: Daniel Clauw, M.D., Professor of Anesthesiology, Medicine and Psychiatry, Director Chronic Pain & Fatigue Research...

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Written by Customer Service on January 25, 2024. Posted in Public Companies.

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Rahway, NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in combination with LAVA-1207, a Gammabody® designed to target the prostate-specific membrane antigen (PSMA) to trigger the potent and preferential killing of PSMA-positive tumor cells, in patients with therapy refractory metastatic castration-resistant prostate cancer (mCRPC). Under the terms of the agreement, Merck &...

Cronos’ Spinach® Brand Ends 2023 as the Number One Flower Brand in Canada1

Written by Customer Service on January 25, 2024. Posted in Public Companies.

TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that its brand, Spinach®, closed 2023 as the number one ranked flower brand in Canada with a 6.9%1 market share in the fourth quarter. Spinach® flower products have resonated strongly with consumers, leading to a significant increase in its ranking from the fourth2 best-selling flower brand in 2022, to become the best-selling flower brand in Canada in 2023. Capturing the leading position in flower rounds out a strong year of growth and innovation for the Spinach® product portfolio, which is ranked as the second best-selling cannabis brand in Canada across all categories as of December 20231. In the fourth quarter, Spinach® products held a number 1 position...

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Written by Customer Service on January 25, 2024. Posted in Public Companies.

Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated patients is anticipated in 2Q 2024Pamrevlumab is the first experimental arm to meet its required threshold for graduation in the seamless Phase 2/3 adaptive platform trialSAN FRANCISCO, Jan. 25, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network’s (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Topline data from this registration study is anticipated in the second quarter of 2024. Pamrevlumab,...

Labrador Gold Intersects 0.87g/t Au Over 55.9 Metres at New HM Occurrence Includes 38.37g/t Au Over 0.8 Meters

Written by Customer Service on January 25, 2024. Posted in Public Companies.

Hole K-23-334 is the only hole drilled into the HM occurrence to dateFigure 1Visible gold grains in quartz vein from Hole K-23-334.Figure 2Mineralized quartz vein intervals in Hole K-23-334.Figure 3Kingsway occurrences with highlights of recent drilling.TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V:LAB | OTCQX:NKOSF | FNR: 2N6) (“LabGold” or the “Company”) is pleased to announce results from recent drilling targeting the highly prospective Appleton Fault Zone. The drilling is part of the Company’s ongoing 100,000 metre diamond drilling program at its 100% owned Kingsway Project. The latest results include holes drilled at Pristine, the NE extension of Big Vein, initial holes at Knobby and Peter Easton as well as the first hole in the new HM occurrence. Hole K-23-334 was a short...

POET Technologies Announces Closing of C$6.2 Million Non-Brokered Private Placement of Units and Reports Preliminary Unaudited Fiscal Fourth Quarter and Fiscal Year 2024 Results

Written by Customer Service on January 25, 2024. Posted in Public Companies.

TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Corporation”) (TSXV:PTK, NASDAQ:POET) is pleased to announce the completion of its non-brokered private placement previously announced on December 11, 2023, pursuant to which an aggregate of 5,098,088 units of the Corporation (the “Units”) were issued at a price of $1.22 (US$0.90) per Unit for an aggregate gross proceeds of approximately C$6.2 million (US$4.6 million) (the “Offering”). Each Unit is comprised of one common share in the capital of the Corporation (each, a “Common Share”) and one Common Share purchase warrant (each, a “Warrant”), with each Warrant entitling the holder thereof to purchase one additional common share of the Corporation (each, a “Warrant Share”)...

Month: January 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals